10:03 AM EDT, 05/13/2025 (MT Newswires) -- Bright Minds Biosciences ( DRUG ) said Tuesday that its BMB-101 showed a complete elimination of drop attacks in the DBA/2 mouse model of epilepsy.

"Notably, BMB-101 achieved 100% survival in the DBA/2 model, reversing brainstem serotonin deficits and preventing seizure-induced respiratory arrest," Jan Torleif Pedersen, the company's chief science officer, said.

The company said the findings demonstrate the potential of BMB-101 to address critical gaps in the prevention of sudden unexpected death in epilepsy.

Shares of Bright Minds Biosciences ( DRUG ) rose more than 11% in recent trading.

Price: 36.43, Change: +3.81, Percent Change: +11.68